Drug Profile
Research programme: PPAR delta agonists - Pfizer
Alternative Names: Research programme: PPAR delta agonists - WyethLatest Information Update: 20 Sep 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class
- Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 20 Sep 2011 No development reported - Preclinical for Obesity in USA (PO)
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 09 Jun 2009 Preclinical trials in Obesity in USA (PO)